Panacea or Pandora's Box?
- Available for pre-order on February 22, 2023. Item will ship after March 15, 2023
Prices & shipping based on shipping country
The book is an introduction to nanomedicine informed by a philosophical reflection about the domain and recent developments. It is an overview of the field, sketching out the main areas of current investment and research. The authors present some case-studies illustrating the different areas of research (nanopharmacy, theranostics and patient monitoring) as well as reflecting on the risks that accompany it, such as unanticipated impacts on human health and environmental toxicity. This introduction to a fast-growing field in modern medical research is of great interest to researchers working in many disciplines as well as the general public. In addition to an overview of the work currently ongoing, the authors critically assess these projects from an ethical and philosophical perspective.
- Provides an overview of nanomedicine
- Employs a reflective and coherent critical evaluation of the benefits and risks of nanomedicine
- Written in an accessible manner intended for a wide audience
Hehenberger, M. Nanomedicine: Science, Business, and impact (ISBN 978-9-8146-1376-7).
Beg, S., et al. Nanomedicine for the treatment of Disease: From Concept to Application (ISBN 978-1-7746-3443-1)
Brenner, S. The Clinical Nanomedicine Handbook (ISBN 978-1-1380-7578-8)
Table of Contents
Chapter 1 Introduction
Chapter 2 Nanopharmacy: What is new with the nano?
Chapter 3 Theranostics: towards a new integrative horizon
Chapter 4 Health under surveillance
Chapter 5 Genetic Nanomedicine
Chapter 6 Toxicology of nanomaterials: a new toxicology?
Chapter 7 Organs on chips, miniaturization and medical specialties. The different logics of nanomedicine
Chapter 8 Regenerative medicine: mobilizing the body’s own repair mechanisms
Chapter 9 Conclusion
Jonathan Simon teaches philosophy of science at the Université de Lorraine (in Nancy) and is a member of the Archives Poincaré (UMR 7117). Trained in the history and philosophy of science at the LSE and in the Department of History and Philosophy of Science of the University of Pittsburgh, he has taught in the US, Australia and France. His research work has been on the history and philosophy of pharmacy and chemistry. https://orcid.org/0000-0003-2265-6863
Bertrand Henri Rihn, MD, DSc, professor of biochemistry and molecular biology at Université de Lorraine, France, is a leading expert in the field of particulate toxicology, with research topics including safety toxicology, mechanistic toxicology and immunotoxicology by investigating transcriptomic changes in macrophages following man-made particles and nanoparticle exposure. He is the head of the ‘Nanomaterials and Health’ team at the Institut Jean-Lamour (Nancy, France) where he is initiating a new research field devoted to the study of the interaction (toxicity and biocompatibility) of macrophages and new implant alloys. In addition to his research, Professor Rihn has also worked as clinical laboratory investigator in bacteriology and virology and is Medical officer-in-Chief at French Defense Central Health Service (Service de Santé des Armées) involved in medical and sanitary support of the French army. He was awarded the Baratz Award (2004) and the Taub Award (2011) from the French National Academy of Medicine and served as the president of the French Society of Toxicology from 2007 to 2009.